Compare IONS & OC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IONS | OC |
|---|---|---|
| Founded | 1989 | 1938 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 12.0B |
| IPO Year | 1996 | 2006 |
| Metric | IONS | OC |
|---|---|---|
| Price | $60.82 | $143.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 11 |
| Target Price | $93.36 | ★ $145.27 |
| AVG Volume (30 Days) | ★ 2.3M | 776.9K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.61% |
| EPS Growth | ★ 21.71 | N/A |
| EPS | N/A | ★ 1.50 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $77.99 | $3.72 |
| P/E Ratio | ★ N/A | $95.79 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.14 | $97.53 |
| 52 Week High | $86.74 | $159.91 |
| Indicator | IONS | OC |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 44.06 |
| Support Level | $50.64 | $135.25 |
| Resistance Level | $78.11 | $145.52 |
| Average True Range (ATR) | 1.80 | 3.87 |
| MACD | 0.95 | -1.53 |
| Stochastic Oscillator | 66.47 | 9.09 |
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Owens-Corning Inc is a building products company that offers roofing products and systems, insulation products (hermal and acoustical batts, loose fill insulation, spray foam insulation, wet use chopped strand, etc.), and doors and door systems. The company's reportable segments are: Roofing, Insulation, and Doors. Maximum revenue is generated from the Roofing segment, which manufactures and sells residential roofing shingles, oxidized asphalt materials, roofing components, and composite lumber mainly used in residential construction. This segment also manufactures and sells glass mat and specialty veil materials used in building and construction applications. Geographically, the company generates maximum revenue from the United States, followed by Europe, Asia-Pacific, and other markets.